CY1106732T1 - Αποστειρωση σωματιδιων του φαρμακου βεκλομεθαζονη για πνευμονικη χορηγηση - Google Patents

Αποστειρωση σωματιδιων του φαρμακου βεκλομεθαζονη για πνευμονικη χορηγηση

Info

Publication number
CY1106732T1
CY1106732T1 CY20071100942T CY071100942T CY1106732T1 CY 1106732 T1 CY1106732 T1 CY 1106732T1 CY 20071100942 T CY20071100942 T CY 20071100942T CY 071100942 T CY071100942 T CY 071100942T CY 1106732 T1 CY1106732 T1 CY 1106732T1
Authority
CY
Cyprus
Prior art keywords
beclomethasone
sterilization
pulmonary administration
drug particles
administration
Prior art date
Application number
CY20071100942T
Other languages
English (en)
Inventor
Marco Gentile
Concetta Dragani Maria
Marco Dell'uomo
Original Assignee
Dompé S.P.A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompé S.P.A filed Critical Dompé S.P.A
Publication of CY1106732T1 publication Critical patent/CY1106732T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A61L2/06—Hot gas
    • A61L2/07—Steam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Περιγράφεται μία μέθοδος για την αποστείρωση αδιάλυτων στο ύδωρ στερεών φαρμακευτικών ουσιών. Η μέθοδος παρέχει την αποστείρωση της βεκλομεθαζόνης η οποία είναι κατάλληλη για πνευμονική χορήγηση. Ειδικότερα, η μέθοδος χρησιμοποιείται σε βιομηχανικές εγκαταστάσεις για την παραγωγή συνθέσεων άσηπτης βεκλομεθαζόνης για χορήγηση δι' εισπνοής, ώστε να αποφευχθούν οποιεσδήποτε τροποποιήσεις της κατανομής μεγέθους σωματιδίων και της εικόνας προσμίξεων του φαρμάκου. Η μέθοδος πραγματοποιείται δια θερμάνσεως ενός μίγματος μικροδιαμερισμένης βεκλομεθαζόνης και καθαρού ύδατος μόνο, κατά προτίμηση σε θερμοκρασία περίπου 120°C επί 20 λεπτά. Η μέθοδος είναι ιδιαίτερα αποτελεσματική και οικονομική για την αποστείρωση με ατμό της διπροπιονικής βεκλομεθαζόνης σε συνθέσεις για πνευμονική χορήγηση.
CY20071100942T 2003-03-04 2007-07-13 Αποστειρωση σωματιδιων του φαρμακου βεκλομεθαζονη για πνευμονικη χορηγηση CY1106732T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03004726A EP1454636A1 (en) 2003-03-04 2003-03-04 Sterilization of glucocorticoid drug particles for pulmonary delivery
PCT/EP2004/050235 WO2004078102A2 (en) 2003-03-04 2004-03-02 Sterilization of beclomethasone drug particles for pulmonary delivery
EP04716254A EP1599233B1 (en) 2003-03-04 2004-03-02 Sterilization of beclomethasone drug particles for pulmonary delivery

Publications (1)

Publication Number Publication Date
CY1106732T1 true CY1106732T1 (el) 2012-05-23

Family

ID=32798759

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100942T CY1106732T1 (el) 2003-03-04 2007-07-13 Αποστειρωση σωματιδιων του φαρμακου βεκλομεθαζονη για πνευμονικη χορηγηση

Country Status (15)

Country Link
US (1) US20060140816A1 (el)
EP (2) EP1454636A1 (el)
JP (1) JP4712689B2 (el)
AT (1) ATE360443T1 (el)
BR (1) BRPI0408022B1 (el)
CY (1) CY1106732T1 (el)
DE (1) DE602004006089T2 (el)
DK (1) DK1599233T3 (el)
ES (1) ES2285436T3 (el)
MX (1) MXPA05009348A (el)
PL (1) PL1599233T3 (el)
PT (1) PT1599233E (el)
RU (1) RU2336905C2 (el)
SI (1) SI1599233T1 (el)
WO (1) WO2004078102A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105809A1 (en) 2003-05-22 2004-12-09 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
GB0410995D0 (en) † 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
GB0425266D0 (en) 2004-11-16 2004-12-15 Norton Healthcare Ltd Pharmaceutical manufacturing process
ES2612257T3 (es) 2011-05-03 2017-05-16 Chiesi Farmaceutici S.P.A. Formulación de suspensión mejorada de dipropionato de beclometasona para administración mediante inhalación
JP5792240B2 (ja) * 2012-08-27 2015-10-07 武夫 西 注射シミュレータ用模擬剤及びその製造方法と製造装置
CA3006251A1 (en) * 2015-12-07 2017-06-15 Emcure Pharmaceuticals Limited Sterile parenteral suspensions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6066292A (en) * 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
IL155935A0 (en) * 2000-11-24 2003-12-23 Breath Ltd A method of sterilizing a pharmaceutical composition
JP4364486B2 (ja) * 2002-07-02 2009-11-18 帝人株式会社 無菌水性懸濁製剤

Also Published As

Publication number Publication date
SI1599233T1 (sl) 2007-10-31
PT1599233E (pt) 2007-07-26
BRPI0408022B1 (pt) 2018-01-23
RU2005130637A (ru) 2006-01-27
BRPI0408022A (pt) 2006-02-14
DE602004006089T2 (de) 2008-01-10
DE602004006089D1 (de) 2007-06-06
US20060140816A1 (en) 2006-06-29
MXPA05009348A (es) 2005-11-04
WO2004078102A3 (en) 2004-11-18
DK1599233T3 (da) 2007-09-17
ATE360443T1 (de) 2007-05-15
ES2285436T3 (es) 2007-11-16
RU2336905C2 (ru) 2008-10-27
WO2004078102A2 (en) 2004-09-16
EP1454636A1 (en) 2004-09-08
EP1599233A2 (en) 2005-11-30
JP2007527364A (ja) 2007-09-27
JP4712689B2 (ja) 2011-06-29
EP1599233B1 (en) 2007-04-25
PL1599233T3 (pl) 2007-10-31

Similar Documents

Publication Publication Date Title
CY1106732T1 (el) Αποστειρωση σωματιδιων του φαρμακου βεκλομεθαζονη για πνευμονικη χορηγηση
Lata et al. Aurora Borealis in dentistry: The applications of cold plasma in biomedicine
NO20063047L (no) Vandige ciclesonidsuspensjoner for forstoving
Bhateja The miraculous healing therapy–“Ozone therapy” in dentistry
CY1111916T1 (el) Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος
CY1108875T1 (el) Βλεννοπροσφυτικα σκευασματα που περιεχουν ξυλογλυκανη και ειναι χρησιμα σε ιατρικες συσκευες και σε φαρμακευτικα σκευασματα
AR037239A1 (es) Composicion de valdecoxib de desintegracion intraoral, proceso para su preparacion, tableta que se obtiene y el uso de dicha composicion en la preparacion de un medicamento.
MX337723B (es) Vacuna de peptido ch3 de ige.
ITMI20022674A1 (it) Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
RG et al. Ozone revisited
EA016596B9 (ru) Получение механоактивированных аморфной и аморфно-кристаллической кальциевых солей глюконовой кислоты
EP1935408A1 (en) Device for the topical application of medical ozone for the treatment of oral cavity diseases
DE502005008500D1 (de) Verwendung von lavendelöl zur prophylaxe und behandlung von somatisierungsstörungen und von posttraumatischer stresserkrankung
CN111838212A (zh) 一种防止气溶胶传播的中药空气消毒净化粉剂
Niveda et al. Comparison of the amount of bacterial microcolonies formed on using distilled water and ozonated water as an irrigating agent.
Najafi Momen et al. Clinical evaluation of the effect of myrtle oil on the oral lesions of FMD in cattle
Salih et al. An Evaluation of the Effectiveness of Coenzyme Q10 Gel in Management of Patients with Chronic Periodontitis (II inter group comparison)
Arora et al. Ozone therapy in dentistry
Aravindhan et al. Anti-Microbial Efficacy Of Ficus Benghalensis And Azadirachta Indica Formulation-An In Vitro Study
MAHENDRA Ozone therapy-an emerging boon in periodontal management.
Machado et al. Evaluation of a Novel Endodontic Paste for Primary Teeth with Necrotic Pulp
Sowmya Evaluation Of Antioxidant Activity Of Oxalis Corniculata-An In Vitro Study
Khan et al. Treatment and control strategies for COVID-19: Prospects and possibilities.
Kumar et al. Ozone Therapy in Oral Diseases: A Reply to Antibiotic Resistance
Valluri et al. UVC based sterilization for hospitals during COVID-19 pandemic for the control of pathogenicity